AbbVie Inc. Total non-current liabilities

Total non-current liabilities of ABBV for past 10 years: annual, quarterly and twelve month trailing (TTM) including Total non-current liabilities growth rates and interactive chart.

Highlights and Quick Summary

  • Total non-current liabilities for the quarter ending September 29, 2019 was $50.2 Billion (a 2.89% increase compared to previous quarter)
  • Year-over-year quarterly Total non-current liabilities decreased by -0.76%
  • Annual Total non-current liabilities for 2018 was $50.6 Billion (a 3.08% increase from previous year)
  • Annual Total non-current liabilities for 2017 was $49 Billion (a -5.1% decrease from previous year)
  • Annual Total non-current liabilities for 2016 was $51.7 Billion (a 35.25% increase from previous year)
Visit for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Total non-current liabilities of AbbVie Inc.

Most recent Total non-current liabilitiesof ABBV including historical data for past 10 years.

Interactive Chart of Total non-current liabilities of AbbVie Inc.

AbbVie Inc. Total non-current liabilities for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2019 $50,174.0 $48,767.0 $50,691.0
2018 $50,559.0 $53,698.0 $47,792.0 $48,731.0 $50,559.0
2017 $49,048.0 $49,120.0 $48,726.0 $51,822.0 $49,048.0
2016 $51,682.0 $51,054.0 $52,299.0 $38,415.0 $51,682.0
2015 $38,211.0 $41,156.0 $37,093.0 $14,272.0 $38,211.0
2014 $14,378.0 $17,174.0 $17,510.0 $17,744.0 $14,378.0
2013 $17,827.0 $17,800.0 $17,547.0 $17,446.0 $17,827.0
2012 $16,869.0 $1,693.25 $1,364.76 $1,395.84 $16,869.0
2011 $1,692.0 $1,692.0
2010 $1,670.45 $1,670.46

Business Profile of AbbVie Inc.

Sector: Medical
Industry: Drugs
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products in the United States, Japan, Germany, Canada, Italy, Spain, the Netherlands, the United Kingdom, Brazil, and internationally. It offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behcet's diseases; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenstrom's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; VIEKIRA PAK, an interferon-free therapy to treat adults with genotype 1 chronic hepatitis C virus (HCV); TECHNIVIE to treat adults with genotype 4 HCV infection; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides KALETRA, an anti-human immunodeficiency virus (HIV)-1 medicine used with other anti-HIV-1 medications to maintain viral suppression in HIV-1 patients; NORVIR, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1; and SYNAGIS to prevent respiratory syncytial virus infection at-risk infants. In addition, it offers AndroGel, a testosterone replacement therapy; CREON, a pancreatic enzyme therapy; Synthroid to treat hypothyroidism; and Lupron to treat prostate cancer, endometriosis, and central precocious puberty, as well as anemia. Further, it provides Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Sevoflurane, an anesthesia product; and ORILISSA, a non-peptide molecule gonadotropin-releasing hormone antagonist. It has collaborations with Alector, Inc.; Janssen Biotech, Inc.; Galapagos; Bristol-Myers Squibb Company; Calico Life Sciences LLC; Cystic Fibrosis Foundation; Dragonfly Therapeutics, Inc.; and Pan-Canadian Pharmaceutical Alliance. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.